Evofem Biosciences

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including non-hormonal, woman-controlled contraception and the prevention of certain sexually transmitted infections (STIs).Evofem Biosciences, Inc.'s first commercialized product, Phexxi™ (lactic acid, citric acid, and potassium bitartrate), is the first and only vaginal pH regulator approved in the United States for the prevention of pregnancy. The company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae (gonorrhea) infections in women.